Nature Communications (Aug 2020)
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
- Tal Noy-Porat,
- Efi Makdasi,
- Ron Alcalay,
- Adva Mechaly,
- Yinon Levy,
- Adi Bercovich-Kinori,
- Ayelet Zauberman,
- Hadas Tamir,
- Yfat Yahalom-Ronen,
- Ma’ayan Israeli,
- Eyal Epstein,
- Hagit Achdout,
- Sharon Melamed,
- Theodor Chitlaru,
- Shay Weiss,
- Eldar Peretz,
- Osnat Rosen,
- Nir Paran,
- Shmuel Yitzhaki,
- Shmuel C. Shapira,
- Tomer Israely,
- Ohad Mazor,
- Ronit Rosenfeld
Affiliations
- Tal Noy-Porat
- Israel Institute for Biological Research
- Efi Makdasi
- Israel Institute for Biological Research
- Ron Alcalay
- Israel Institute for Biological Research
- Adva Mechaly
- Israel Institute for Biological Research
- Yinon Levy
- Israel Institute for Biological Research
- Adi Bercovich-Kinori
- Israel Institute for Biological Research
- Ayelet Zauberman
- Israel Institute for Biological Research
- Hadas Tamir
- Israel Institute for Biological Research
- Yfat Yahalom-Ronen
- Israel Institute for Biological Research
- Ma’ayan Israeli
- Israel Institute for Biological Research
- Eyal Epstein
- Israel Institute for Biological Research
- Hagit Achdout
- Israel Institute for Biological Research
- Sharon Melamed
- Israel Institute for Biological Research
- Theodor Chitlaru
- Israel Institute for Biological Research
- Shay Weiss
- Israel Institute for Biological Research
- Eldar Peretz
- Israel Institute for Biological Research
- Osnat Rosen
- Israel Institute for Biological Research
- Nir Paran
- Israel Institute for Biological Research
- Shmuel Yitzhaki
- Israel Institute for Biological Research
- Shmuel C. Shapira
- Israel Institute for Biological Research
- Tomer Israely
- Israel Institute for Biological Research
- Ohad Mazor
- Israel Institute for Biological Research
- Ronit Rosenfeld
- Israel Institute for Biological Research
- DOI
- https://doi.org/10.1038/s41467-020-18159-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 7
Abstract
Here, Noy-Porat, Makdasi et al. report the isolation of a panel of neutralizing mAbs selected against SARS-CoV-2 receptor-binding domain (RBD) from a phage display library constructed based on patient samples collected in the acute phase of the disease, which show efficient neutralizing activities against authentic virus in vitro.
